News | Radiation Oncology | April 17, 2020

PTW announces first North American installation and FDA 510(k) clearance of Beamscan MR motorized 3-D water phantom

PTW announces first North American installation and FDA 510(k) clearance of Beamscan MR motorized 3-D water phantom

PTW Beamscan MR for Elekta Unity


April 17, 2020 — PTW has installed the first Beamscan MR motorized 3-D water phantom in North America at the Princess Margaret Cancer Centre in Toronto, Ontario, Canada. In addition, PTW announces that the Beamscan MR water phantom recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for sale within the United States. The Beamscan MR motorized 3-D water phantom provides a dedicated, fully equipped solution for beam data commissioning and annual QA of MR-LINACs.

The Princess Margaret Cancer Centre is part of the University Health Network, which is affiliated with the University of Toronto. It is one of the largest comprehensive cancer treatment facilities in the world and the largest radiation treatment facility in Canada. It houses two state-of-the-art MR-LINAC systems: an Elekta Unity system as well as an MR-on-rail system combined with a linear accelerator and a brachytherapy afterloader (MRgRT system).

“We invested in the Beamscan MR because it is an essential tool for the commissioning and maintenance of our Elekta Unity MR-LINAC,” said Daniel Létourneau Ph.D., head of physics in the Radiation Medicine Program at Princess Margaret Cancer Centre. Létourneau leads clinical operations as well as the academic and education activities of the Medical Physics Department at the Princess Margaret Cancer Centre.

“The Beamscan MR enables us to conduct in-depth radiation beam characterization and quality assurance of our Unity MR-LINAC,” Létourneau added. “Because it is designed for compatibility with the Elekta Unity, we can perform accurate beam profile and depth-dose curve measurements in the specific geometry of the MR-LINAC.”

The Beamscan MR water phantom is available for both the Elekta Unity and ViewRay MRIdian MR-LINACs. It is the first motorized 3-D water phantom suitable for clinical use in a 1.5 T MR environment. The Beamscan MR phantom comes ready to use on a single carriage and includes everything needed for operation. 

PTW is continuously developing innovative dosimetry solutions to deliver fast, precise measurements for complex radiation equipment and treatment plans. PTW delivers a full line of dosimetry solutions for acceptance testing, beam data commissioning, and machine- and patient-specific QA.

For more information: www.ptwdosimetry.com


Related Content

News | RSNA 2025

Nov. 13, 2025 — Nano-X Imaging Ltd., a medical imaging technology company, will showcase its Nanox.ARC X multi-source ...

Time November 25, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
News | Lung Imaging

Nov. 3, 2025 — RevealDx, a leader in the characterization of lung nodules, has introduced MDR Certification of RevealAI ...

Time November 07, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Feature | Teleradiology | Kyle Hardner

Once viewed as a solution for after-hours coverage, teleradiology is rapidly expanding into a critical part of radiology ...

Time November 06, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
Subscribe Now